CROCC

Across TCGA pan-cancer cohorts, CROCC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CROCC data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CROCC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CROCC expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where CROCC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.779	0.418	.004	20	view →
GBM	DFS	Median	All	0.466	0.274	.012	11	view →
LUAD	DFS	Quartile	II,III,IV	0.763	0.994	.013	7	view →
PDAC	OS	Median	II,III,IV	0.266	0.511	.010	6	view →
OV	DFS	Median	All	1.000	0.837	.018	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.833	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CROCC–CCRCC (DFS)

Open the CCRCC breakdown →